Kindeva Drug Delivery and Koura Global parent company Orbia Advance Corporation announced that they have partnered to convert a currently marketed metered dose inhaler to use Koura’s HFA 152a (Zephex 152a), a lower global warming potential (LGWP) propellant. According to the announcement, the collaboration “aims to facilitate conversion of pMDI products to the lower GWP propellent 152a and progressing them through clinical development.” The companies said that MDIs converted to HFA 152a will be available to license.
In August 2023, Kindeva announced that it had received a grant from the UK’s Life Sciences Innovation Manufacturing Fund that would be used to increase the company’s LGWP MDI manufacturing capacity. Kindeva announced in November 2021 that it would install an LGWP MDI filling line to fill either HFA-152a or HFO-1234ze. In early 2022, the company announced that it would install a second LGWP line.
Kindeva Global Chief Commercial Officer David Stevens commented, “We are proud to partner with Koura to help achieve the dual objectives of significantly reducing the environmental impact of pMDI inhalers and ensuring patient access to inhaler options is not compromised. Kindeva has a rich history of innovation in the pMDI market and our comprehensive development and manufacturing capabilities uniquely enable us to help lead this transition. This strategic collaboration is symbolic of not only the commitment both partners have for advancing sustainability and advocating for patient choice, but also of the shared values of the two organizations.”
Orbia Fluorinated Solutions Business (Koura) President Gregg Smith said, “This is a significant step forward in bringing our lower GWP medical propellant Zephex 152a to the market and we are excited to partner with Kindeva to ensure patients have access to this life saving technology.”
Read the Kindeva Drug Deliverly and Orbia press release.
